2 citations
,
April 2021 in “Canadian Journal of Urology” This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.
38 citations
,
October 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.
February 2026 in “NeuroSci” This systematic review synthesizes evidence on the distribution of 5a-reductase isozymes and their implications for mental health, finding that inhibition of neurosteroidogenesis may contribute to anxiety, depression, and suicidality, with some patients experiencing persistent psychiatric effects from finasteride or dutasteride.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.
7 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.
January 2023 in “Dermatologic Therapy” This review found that intralesional corticosteroid injections and 5-alpha-reductase inhibitors were reported as the most effective treatments for frontal fibrosing alopecia, with oral isotretinoin showing promise for facial papule improvement.
This study suggests that 5AR inhibitors may reverse decreased expression of growth factor genes in human hair follicles under testosterone stimulation, indicating involvement of type I 5AR in hair growth.
November 2012 in “Endocrine Practice” This review outlines the physiological roles of 5a-reductases and highlights the need for further research to better understand their function and minimize adverse effects from their inhibitors used in treatment.
May 2026 in “Reactions Weekly” April 2026 in “Reactions Weekly” December 2024 in “Reactions Weekly” November 2014 in “Reactions Weekly” July 2014 in “Reactions Weekly” August 2013 in “Reactions Weekly” January 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly” August 2012 in “Reactions Weekly” March 2012 in “Reactions Weekly” August 2011 in “Reactions Weekly” May 2011 in “Reactions Weekly” April 2011 in “Reactions Weekly” March 2011 in “Reactions Weekly” April 2010 in “Reactions Weekly” September 2009 in “Reactions Weekly” August 2009 in “Reactions Weekly” February 2009 in “Reactions Weekly” October 2008 in “Reactions Weekly” October 2008 in “Reactions Weekly” February 2008 in “Reactions Weekly” November 2007 in “Reactions Weekly”